Immunocal® and preservation of Glutathione as a novel neuroprotective strategy for degenerative disorders of the nervous system

Recent Patents on CNS Drug Discovery

Volumn 7, Issue 3, 2012, Pages 230-235

  Ross, Erika K ^a   Gray, Josie J ^a   Winter, Aimee N ^a   Linseman, Daniel A ^a,b  

^a UNIVERSITY OF DENVER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antioxidant; Cysteine; Cystine; Glutathione; Immunocal; Neurodegeneration; Neuroprotection; Oxidative stress; Whey protein

Indexed keywords

GLUTATHIONE; IMMUNOCAL; NUTRACEUTICAL; UNCLASSIFIED DRUG;

BRAIN METABOLISM; DEMYELINATING DISEASE; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG RESEARCH; DRUG STABILITY; GLUTATHIONE METABOLISM; HUMAN; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIOXIDANTS; DIETARY SUPPLEMENTS; GLUTATHIONE; HUMANS; MILK PROTEINS; NERVOUS SYSTEM; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PATENTS AS TOPIC;

EID: 84867786654     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488912803252014     Document Type: Review

References (77)

1. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443(7113): 787-95.
2. Karbowski M, Neutzner A. Neurodegeneration as a consequence of failed mitochondrial maintenance. Acta Neuropathol 2012; 123(2): 157-71.
3. Gutteridge JM, Halliwell B. Free radicals and antioxidants in the year 2000. A historical look to the future. Ann N Y Acad Sci 2000; 899: 136-47.
4. Adibhatla RM, Hatcher JF. Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 2010; 12(1): 125-69.
5. Lezi E, Swerdlow RH. Mitochondria in neurodegeneration. Adv Exp Med Biol 2012; 942: 269-86.
6. Cassarino DS, Bennett JP. An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res Brain Res Rev 1999; 29(1): 1-25.
7. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995; 38(3): 357-66.
8. Bindoff LA, Birch-Machin MA, Cartlidge NE, Parker WD, Turnbill DM. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. J Neurol Sci 1991; 104(2): 203-8.
9. Lax P, Esquiva G, Esteve-Rudd J, Otalora BB, Madrid JA, Cuenca N. Circadian dysfunction in a rotenone-induced parkinsonian rodent model. Chronobiol Int 2012; 29(2): 147-56.
10. Ali SF, David SN, Newport GD, Cadet JL, Slikker W. MPTPinduced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels. Synapse 1994; 18(1): 27-34.
11. Bartley MG, Marquardt K, Kirchof D, Wilkins HM, Patterson D, Linseman DA. Overexpression of amyloid-beta protein precursor induces mitochondrial oxidative stress and activates the intrinsic apoptotic cascade. J Alzheimers Dis 2012; 28(4): 855-68.
12. Ansari MA, Scheff SW. Oxidative stress in the progression of Alzheimer's disease in the frontal cortex. J Neuropathol Exp Neurol 2010; 69(2): 155-67.
13. Eckert A, Keil U, Marques CA, Bonert A, Frey C, et al. Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochem Pharmacol 2003; 66(8): 1627-34.
14. Dumont M, Beal MF. Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic Biol Med 2011; 51(5): 1014-26.
15. Schmitt K, Grimm A, Kazmierczak A, Strosznajder JB, Gotz J, Eckert A. Insights into Mitochondrial Dysfunction: Aging, Amyloid-beta, and Tau-A Deleterious Trio. Antioxid Redox Signal 2012.
16. Meister A. New aspects of glutathione biochemistry and transport--selective alteration of glutathione metabolism. Nutr Rev 1984; 42(12): 397-410.
17. Takahashi M. Oxidative stress and redox regulation on in vitro development of Mammalian embryos. J Reprod Dev 2012; 58(1): 1-9.
18. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J Nutr 2004; 134(3): 489-92.
19. Griffith OW. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic Biol Med 1999; 27(9-10): 922-35.
20. Kehrer JP, Lund LD. Cellular reducing equivalents and oxidative stress. Free Radic Biol Med 1994; 17(1): 65-75.
21. Schulz JB, Lindenau J, Seyfried J, Dichgans J. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem 2000; 267(16): 4904-11.
22. Kamboj SS, Vasishta RK, Sandhir R. N-acetylcysteine inhibits hyperglycemia-induced oxidative stress and apoptosis markers in diabetic neuropathy. J Neurochem 2010; 112(1): 77-91.
23. Welin D, Novikova LN, Wiberg M, Kellerth JO, Novikov LN. Effects of N-acetyl-cysteine on the survival and regeneration of sural sensory neurons in adult rats. Brain Res 2009; 1287: 58-66.
24. Sandhir R, Sood A, Mehrotra A, Kamboj SS. N-Acetylcysteine reverses mitochondrial dysfunctions and behavioral abnormalities in 3-nitropropionic acid-induced huntington's disease. Neurodegener Dis 2012; 9(3): 145-57.
25. Sun L, Gu L, Wang S, Yuan J, Yang H, et al. N-acetylcysteine Protects against Apoptosis through Modulation of Group I Metabotropic Glutamate Receptor Activity. PLoS One 2012; 7(3): e32503.
26. Olivieri G, Baysang G, Meier F, Muller-Spahn F, Stahelin HB, Brockhaus M, et al. N-acetyl-L-cysteine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: effects on beta-amyloid secretion and tau phosphorylation. J Neurochem 2001; 76(1): 224-33.
27. Andreassen OA, Dedeoglu A, Klivenyi P, Beal MF, Bush AI. Nacetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport 2000; 11(11): 2491-3.
28. Anderson MF, Nilsson M, Eriksson PS, Sims NR. Glutathione monoethyl ester provides neuroprotection in a rat model of stroke. Neurosci Lett 2004; 354(2): 163-5.
29. Anderson MF, NilssonM, Sims NR. Glutathione monoethylester prevents mitochondrial glutathione depletion during focal cerebral ischemia. Neurochem Int 2004; 44(3): 153-9.
30. Guizar-Sahagun G, Ibarra A, Espitia A, Martinez A, Madrazo I. Glutathione monoethyl ester improves functional recovery, enhances neuron survival, and stabilizes spinal cord blood flow after spinal cord injury in rats. Neurosci 2005; 130(3): 639-49.
31. Rothstein JD. Therapeutic horizons for amyotrophic lateral sclerosis. Curr Opin Neurobiol 1996; 6(5): 679-87.
32. Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Truffinet P, et al. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol 2002; 249(5): 609-15.
33. Tandan R, Bradley WG. Amyotrophic lateral sclerosis: Part 1. Clinical features, pathology, and ethical issues in management. Ann Neurol 1985; 18(3): 271-80.
34. Cozzolino M, Carri MT. Mitochondrial dysfunction in ALS. Prog Neurobiol 2011.
35. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A. Amyotrophic lateral sclerosis. Lancet 2011; 377(9769): 942-55.
36. Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med 2010; 48(5): 629-41.
37. Babu GN, Kumar A, Chandra R, Puri SK, Singh RL, Kalita J, et al. Oxidant-antioxidant imbalance in the erythrocytes of sporadic amyotrophic lateral sclerosis patients correlates with the progression of disease. Neurochem Int 2008; 52(6): 1284-9.
38. Cova E, Bongioanni P, Cereda C, Metelli MR, Salvaneschi L, Bernuzzi S, et al. Time course of oxidant markers and antioxidant defenses in subgroups of amyotrophic lateral sclerosis patients. Neurochem Int 2010; 56(5): 687-93.
39. Iguchi Y, Katsuno M, Takagi S, Ishigaki S, Niwa JI, et al. Oxidative stress induced by glutathione depletion reproduces pathological modifications of TDP-43 linked to TDP-43 proteinopathies. Neurobiol Dis 2012; 45(3): 862-870.
40. Oeda T, Shimohama S, Kitagawa N, Kohno R, Imura T, Shibasaki H, et al. Oxidative stress causes abnormal accumulation of familial amyotrophic lateral sclerosis-related mutant SOD1 in transgenic Caenorhabditis elegans. Hum Mol Genet 2001; 10(19): 2013-23.
41. D'Alessandro G, Calcagno E, Tartari S, Rizzardini M, Invernizzi RW, Cantoni L. Glutamate and glutathione interplay in a motor neuronal model of amyotrophic lateral sclerosis reveals altered energy metabolism. Neurobiol Dis 2011; 43(2): 346-55.
42. Fischer LR, Li Y, Asress SA, Jones DP, Glass JP. Absence of SOD1 leads to oxidative stress in peripheral nerve and causes a progressive distal motor axonopathy. Exp Neurol 2012; 233(1): 163-71.
43. Tateishi N, Higashi T, Shinya S, Naruse A, Sakamoto Y. Studies on the regulation of glutathione level in rat liver. J Biochem 1974; 75(1): 93-103.
44. Bounous G, Gold P. The biological activity of undenatured dietary whey proteins: role of glutathione. Clin Invest Med 1991; 14(4): 296-309.
45. Bounous G, Kongshavn PA. The effect of dietary amino acids on immune reactivity. Immunol 1978; 35(2): 257-66.
46. th ed. PDR Network. 2012.
47. Floyd RA. Role of oxygen free radicals in carcinogenesis and brain ischemia. FASEB J 1990; 4(9): 2587-97.
48. Ramos S. Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol Nutr Food Res 2008; 52(5): 507-26.
49. Papenburg R, Bounous G, Fleiszer D, Gold P. Dietary milk proteins inhibit the development of dimethylhydrazine-induced malignancy. Tumour Biol 1990; 11(3): 129-36.
50. Tsai WY, Chang WH, Chen CH, Lu FJ. Enchancing effect of patented whey protein isolate (Immunocal) on cytotoxicity of an anticancer drug. Nutr Cancer 2000; 38(2): 200-08.
51. Tozer RG, Tai P, Falconer W, Ducruet T, Karabadjian A, et al. Cysteine-rich protein reverses weight loss in lung cancer patients receiving chemotherapy or radiotherapy. Antioxid Redox Signal 2008; 10(2): 395-402.
52. Baruchel S, Bounous G, Gold P. Place for an antioxidant therapy in human immunodeficiency virus (HIV) infection. J Nutr 1994; 112: 1747-55.
53. Bounous G, Baruchel S. "Whey proteins as a food supplement in HIV-seropositive individuals. " Clin Invest Med 1993; 16(3): 204-209.
54. Lands LC, Grey VL, Smountas AA. Effect of supplementation with a cysteine donor on muscular performance. J Appl Physiol 1999; 87(4): 1381-5.
55. Grey V, Mohammed SR, Smountas AA, Bahlool R, Lands LC. Improved glutathione status in young adult patients with cystic fibrosis supplemented with whey protein. J Cyst Fibros 2003; 2(4): 195-8.
56. Bounous G, Gervais F, Amer V, Batist G, Gold P. The influence if dietary whey protein on tissue glutathione and the diseases of aging. Clin Invest Med 1989; 12: 343-9.
57. Gold, P., Bounous, G., Kongshavn, P.A.L. Undenatured whey protein concentrate to improve active systemic humoral immune response. US5230902 (1990).
58. Bounous, G., Gold, P. Method of treatment if HIV-seropositive individuals with dietary whey protein. US5456924 (1992).
59. Bounous, G., Gold, P. Anti-cancer therapeutic compositions containing whey protein concentration. US5888552 (1999).
60. Guilford, T.F., Keller, B.C. Liposome-encapsulated glutathione for oral administration. US0305752 (2011).
61. Crum, A. Nutritional or therapeutic compositions to increase bodily glutathione levels. US0029082 (2012).
62. Lombard, J.L. Medical foods for the treatment of developmentallybased neuropsychiatric disorders via modulation of brain glycine and glutathione pathways. US0041066 (2012).
63. Mari M, Morales A, Colell A, Garcia-Ruiz C, Fernández-Checa JC. Mitochondrial glutathione, a key survival antioxidant. Antioxid Redox Signal 2009 11: 2685-700.
64. Cudkowicz ME, Sexton PM, Ellis T, Hayden DL, Gwilt PR, et al. The pharmacokinetics and pharmaco-dynamics of Procysteine in amyotrophic lateral sclerosis. Neurol 1999; 52(7): 1492-4.
65. Wild AC, Moinova HR, Mulcahy RT. Regulation of gammaglutamylcysteine synthetase subunit gene expression by the transcription factor Nrf2. J Biol Chem 1999; 274(47): 33627-36.
66. Jaiswal AK. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med 2004; 36(10): 1199-207.
67. Arredondo F, Echeverry C, Abin-Carriquiry JA, Blasina F, Antunez K, et al. After cellular internalization, quercetin causes Nrf2 nuclear translocation, increases glutathione levels, and prevents neuronal death against an oxidative insult. Free Radic Biol Med 2010; 49(5): 738-47.
68. Greco T, Fiskum G. Neuroprotection through stimulation of mitochondrial antioxidant protein expression. J Alzheimers Dis 2010; 20 Suppl 2: S427-437.
69. Vargas MR, Johnson DA, Sirkis DW, Messing A, Johnson JA. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci 2010; 28(50): 13574-81.
70. Neymotin A, Calingasan NY, Wille E, Naseri N, Petri S, et al. Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic Biol Med 2011; 51(1): 88-96.
71. Watabe M, Aoyama K, Nakaki T. A dominant role of GTRAP3-18 in neuronal glutathione synthesis. J Neurosci 2008; 28(38): 9404-13.
72. Aoyama K, Wang F, Matsumura N, Kiyonari H, Shioi G, Tanaka K. Increased neuronal glutathione and neuroprotection in GTRAP3-18-deficient mice. Neurobiol Dis 2012; 45(3): 973-82.
73. Kamboj SS, Sandhir R. Protective effect of N-acetylcysteine supplementation on mitochondrial oxidative stress and mitochondrial enzymes in cerebral cortex of streptozotocin-treated diabetic rats. Mitochondrion 2011; 11(1): 214-22.
74. Henderson JT, Javaheri M, Kopko S, Roder JC. Reduction of lower motor neuron degeneration in wobbler mice by N-acetyl-Lcysteine. J Neurosci 1996; 16(23): 7574-82.
75. G93A ALS mouse model. (Meeting Abstract) Society for Neuroscience Meeting. Washington, D.C., USA (2011).
76. Vargas MR, Johnson DA, Johnson JA. Decreased glutathione accelerates neurological deficit and mitochondrial pathology in familial ALS-linked hSOD1(G93A) mice model. Neurobiol Dis 2011; 43(3): 543-51.
77. Silva LB, Mourao LF, Silva AA, Lima NM, Almeida SR, et al. Effect of nutritional supplementation with milk whey proteins in amyotrophic lateral sclerosis patients. Arq Neuropsiquiatr 2010; 68(2): 263-8.